Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen; Gang Jia; Xilin Zhang; Wenxue Ma

doi:10.3389/fimmu.2024.1376045

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Front Immunol. 2024 Jan 31:15:1376045. doi: 10.3389/fimmu.2024.1376045. eCollection 2024.

Authors

Qiuqiang Chen¹, Gang Jia², Xilin Zhang¹, Wenxue Ma³

Affiliations

¹ Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China.
² Department of Medical Oncology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
³ Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

Keywords: Patritumab Deruxtecan (HER3-DXd); antibody-drug conjugates (ADCs); epidermal growth factor receptor (EGFR); human EGFR3 (HER3); non-small cell lung cancer (NSCLC); receptor tyrosine kinases (RTKs); resistance; tyrosine kinase inhibitors (TKIs).

Publication types

Published Erratum